GPL Holdings is a preclinical-stage biopharmaceutical company with no revenue, no approved products, and one employee. The company operates through its wholly owned subsidiary, Global Pharma Labs, and aims to develop and sell low-cost pharmaceutical products, including prescription drugs, non-prescription drugs, medical supplies, dental supplies, and medical equipment. GPL Holdings' lead candidate is OA-sys, a therapy for osteoarthritis that has not yet entered human clinical trials. The company also plans to pursue therapies for nail fungus, genital herpes, and erectile dysfunction, though these are at an even earlier stage with no patent applications filed. GPL Holdings' intended business model is to develop therapies, secure patents and regulatory approvals, and then sell or distribute products — either independently or through Vitam Dandum Global Pharma Labs, a Zambia-based entity controlled by sole officer and director Sylvester Crawford. Crawford also personally owns the patents licensed to the company, though all of those patents are either expired, abandoned, or lapsed, meaning none are currently in good standing. The flagship OA-sys patents have fully expired and cannot be revived. GPL Holdings has no marketing or sales infrastructure, requires at least $500,000 to pursue near-term goals, and has been funded entirely by Crawford personally with no formal obligation for him to continue. The company plans to raise capital through Regulation CF or Regulation A offerings.